124 related articles for article (PubMed ID: 2774869)
1. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
Oelschläger H; Rothley D; Schmidt W
Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
[No Abstract] [Full Text] [Related]
3. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
[TBL] [Abstract][Full Text] [Related]
4. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
[TBL] [Abstract][Full Text] [Related]
5. [The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate].
Oelschläger H; Hellwich KH; Rothley D
Arch Pharm (Weinheim); 1994 Apr; 327(4):261-5. PubMed ID: 8204026
[TBL] [Abstract][Full Text] [Related]
6. [Conjugation reactions of ciprofibrate with human and laboratory animals].
Oelschläger H; Müller D; Hellwich KH; Ueberall S; Seeling A; Machts H; Hofmann B; Glöckner R
Arzneimittelforschung; 2003; 53(4):247-53. PubMed ID: 12785120
[TBL] [Abstract][Full Text] [Related]
7. The effect of ciprofibrate on gastric secretion in the rat.
Eason CT; Pattison A; Howells DD; Bonner FW
J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ciprofibrate and clofibric acid as peroxisomal proliferators in primary cultures of rat hepatocytes.
Feller DR; Singh Y; Shirhatti VR; Kocarek TA; Liu CT; Krishna G
Hepatology; 1987; 7(3):508-16. PubMed ID: 3570161
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
Arnold A; McAuliff MP; Beyler AL
J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
[TBL] [Abstract][Full Text] [Related]
10. [Amino acid derivatives of 2-(p-chlorophenoxy)-2-methylpropionic acid as compounds with potential antilipemic agents. II. Preparation of methyl esters of N-[2-(p-chlorophenoxy)-2-methylpropionyl] amino acids].
Kwapiszewski W; Borkowski L
Acta Pol Pharm; 1987; 44(2):121-31. PubMed ID: 3434313
[No Abstract] [Full Text] [Related]
11. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
Awasthi YC; Singh SV; Goel SK; Reddy JK
Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
[TBL] [Abstract][Full Text] [Related]
12. [The pharmacokinetics of antilipemic agents. 8. Unequivocal characterization of ciprofibrate-O-beta-d-glucuronide].
Oelschläger H; Kohl C; Armstrong DW; Rothley D
Arch Pharm (Weinheim); 1991 Aug; 324(8):505-8. PubMed ID: 1781732
[TBL] [Abstract][Full Text] [Related]
13. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
[TBL] [Abstract][Full Text] [Related]
14. Determination of ciprofibrate in human plasma by high-performance liquid chromatography.
Park GB; Biddlecome CE; Koblantz C; Edelson J
J Chromatogr; 1982 Feb; 227(2):534-9. PubMed ID: 7061664
[No Abstract] [Full Text] [Related]
15. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
Rao MS; Dwivedi RS; Subbarao V; Reddy JK
Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
[TBL] [Abstract][Full Text] [Related]
16. Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats.
Srinivasan SR; Chow CK; Glauert HP
Toxicology; 1990 Jun; 62(3):321-32. PubMed ID: 2389247
[TBL] [Abstract][Full Text] [Related]
17. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate.
Spencer AJ; Barbolt TA; Henry DC; Eason CT; Sauerschell RJ; Bonner FW
Toxicol Pathol; 1989; 17(1 Pt 1):7-15. PubMed ID: 2501865
[TBL] [Abstract][Full Text] [Related]
18. Achiral and chiral determination of ciprofibrate and its glucuronide in human urine by capillary electrophoresis.
Hüttemann H; Blaschke G
J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):33-41. PubMed ID: 10410925
[TBL] [Abstract][Full Text] [Related]
19. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Orö L
Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
[TBL] [Abstract][Full Text] [Related]
20. In vivo distribution of a carcinogenic hepatic peroxisome proliferator: whole-body autoradiography of [14C]ciprofibrate in the mouse.
Waddell WJ; Marlowe C; Rao MS; Reddy JK
Carcinogenesis; 1989 Jan; 10(1):221-3. PubMed ID: 2910527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
